Recombinant Human IL-21-expressing Oncolytic Vaccinia Virus Injection (hV01) in Advanced Pancreatic Cancer

Clinical trial NCT07006077 · RECRUITING

Trial details

NCT number: NCT07006077
Sponsor: Hangzhou Converd Co., Ltd.
Status: RECRUITING
Phase: Phase 2
Study type: INTERVENTIONAL

Advanced Pancreatic Cancer

Start date: 2025-05-29
Primary completion: 2028-12-31
Enrollment: 12

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.